about
Histone 3.3 hotspot mutations in conventional osteosarcomas: a comprehensive clinical and molecular characterization of six H3F3A mutated cases.IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO.Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets.TERT Promoter Mutations and Risk of Recurrence in Meningioma.Molecular Transition of an Adult Low-Grade Brain Tumor to an Atypical Teratoid/Rhabdoid Tumor Over a Time-Course of 14 Years.DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.SHH desmoplastic/nodular medulloblastoma and Gorlin syndrome in the setting of Down syndrome: case report, molecular profiling, and review of the literature.Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity.Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis.Methylation-based classification of benign and malignant peripheral nerve sheath tumors.AT-10ATYPICAL TERATOID RHABDOID TUMORS AND POORLY DIFFERENTIATED CHORDOMAS: DISTINCT MOLECULAR ENTITIES WITH SMARCB1/INI1 LOSS AND DISMAL PROGNOSIS.MB-26SHH DESMOPLASTIC/NODULAR MEDULLOBLASTOMA AND GORLIN SYNDROME IN THE SETTING OF DOWN SYNDROME: CASE REPORT WITH MOLECULAR PROFILING.Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter-hypermethylation - the NCT Neuro Master Match (N2M2) pilot study.Design of clinical studies: adaptive randomization and progression-free survival (PFS) as an endpoint in clinical studies of advanced non-small cell lung cancer (NSCLC).Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo.Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas.ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.Melanotic tumors of the nervous system are characterized by distinct mutational, chromosomal and epigenomic profiles.Malignant Transformation of a Dysembryoplastic Neuroepithelial Tumor (DNET) Characterized by Genome-Wide Methylation Analysis.H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers.Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature.Adaptive randomization procedures for the web-based randomization system RANDI2.Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.Array-based DNA-methylation profiling in sarcomas with small blue round cell histology provides valuable diagnostic information.Molecular characterization of medulloblastomas with extensive nodularity (MBEN).Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.DNA methylation-based classification of central nervous system tumours.Synchronous pituitary adenoma and pituicytoma.Somatic mutations of DICER1 and KMT2D are frequent in intraocular medulloepitheliomas.FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma.Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience.Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas.Genome-wide methylation profiling and copy number analysis in atypical fibroxanthomas and pleomorphic dermal sarcomas indicate a similar molecular phenotypeMethylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centreACTR-05. THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA.
P50
Q33640720-D589A7D9-39DB-489D-AFC1-EC4AB1173C7BQ35845197-C230EDE7-4CD9-4CF7-8ACA-AFE7D48210ADQ35869744-F551DD5B-4C59-42B4-A4EE-64FCD4899D6DQ36849156-799FCB95-5346-4DCC-818B-1A8B884578D3Q38633637-187C29CD-F4E2-41D8-8C8A-202DB233246DQ38743450-3AC7D6C7-B6CD-493F-AB94-F97C20EE9EDCQ38904944-5B449B0E-02A8-4379-9461-D513A6E305F3Q38951877-53FA2A63-0F2F-44EE-B28F-CBD6C8B12696Q40822804-B671FD94-E09C-4410-875A-307A5CCFF0C9Q41264935-9045E300-25C8-45D1-BA80-F3633E0D72F1Q46001867-742D1836-F1C8-498B-B848-C6ECC259F8C8Q46088787-CFC92923-4983-4746-8952-E96FDF7E11EAQ46347720-5A359C58-E915-4204-B5DD-F4A7B735AB26Q46354438-6C0BD93F-E362-4945-B4E0-26E57E024320Q47374036-C8788802-FB11-42E2-8162-B43A8942E8C3Q48332194-84617172-7AFF-48DD-9BD5-00CE2BE1462BQ48339218-AF04CEBE-8998-4EC6-B593-410BBB627C1FQ48387987-3EEFC6E1-EC7A-4759-AFD5-A89F791B3AABQ48446221-4DCF83BD-103F-446D-BAEF-5A784A29DEF4Q48455596-05CCDA60-AF49-457A-854D-79F24E731010Q48874437-5AA8B821-22F2-49E1-8ABB-BCC50FEDAF41Q50733824-56A4F648-4E44-4940-B882-C61476525D16Q51019249-1990AB1F-2450-4C81-858F-A642EB23436EQ51466320-7DD83F18-0DBC-4494-AC4F-BE538DF87245Q52567998-677B8E7F-3EFF-4E31-9DD2-ED3683F914C0Q52639371-83FF8474-5B30-44D4-AC4A-30DC545EA026Q52641215-5DA276E1-E4BF-4A8F-A9CE-59CE8BFB9DA5Q52643311-04B53DD6-A839-467C-A1A7-5881ED9E4FB1Q52655770-54742EF8-8964-48CA-9B40-F2E171952246Q53307963-F21F3F05-E2F3-401B-A2F1-987380A5F28AQ54217156-58F87F8E-411A-41F2-952F-E5FE14BF95B8Q55456682-5975D576-0C22-46AF-A709-128141A5112CQ55456692-19C3DBCC-82D3-4A95-9139-89283E9AA623Q55457176-0A00FCA3-C5D1-4C3F-B37F-480CE021494DQ64243350-01BDBA64-E0E6-4FC9-B8C1-A7B07E815039Q64260247-79BEF4C7-BC92-45F6-9EA7-A9C1BA502832Q64992343-D05C1F27-8376-42E6-9640-364BF41E4A6C
P50
name
Daniel Schrimpf
@ast
Daniel Schrimpf
@en
Daniel Schrimpf
@es
Daniel Schrimpf
@nl
type
label
Daniel Schrimpf
@ast
Daniel Schrimpf
@en
Daniel Schrimpf
@es
Daniel Schrimpf
@nl
prefLabel
Daniel Schrimpf
@ast
Daniel Schrimpf
@en
Daniel Schrimpf
@es
Daniel Schrimpf
@nl